Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.69 |
| ▸ | CCND1 | P24385 | 19/20 | 0.69 |
| ▸ | CCND2 | P30279 | 17/20 | 0.69 |
| ▸ | CCND3 | P30281 | 17/20 | 0.69 |
| ▸ | CDK2 | P24941 | 5/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.48 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.48 |
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.48 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807804 | 0.91 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6807795 | 0.89 | CDK4 (0.66) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6804414 | 0.88 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6808945 | 0.88 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6808461 | 0.87 | CDK4 (0.67) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6808027 | 0.86 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6808868 | 0.86 | CDK4 (0.69) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6807805 | 0.84 | CDK4 (0.63) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL6809354 | 0.82 | CDK4 (0.72) | CDK4CCND1CCND2CCND3CDK2 | |
| SCHEMBL5264058 | 0.82 | CDK4 (1.00) | CDK4CCND1CCND2CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | claimed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | claimed |
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | BOOTH RICHARD JOHN (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1255755-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001055148-A1 | PYRIDOPYRIMIDINONE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASE | WARNER-LAMBERT COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224958-A1 | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease | CDK4, CDKL1, CCNT1 | CDK4 1/4885CCND1 23/4885CCND2 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.